

Oliver Peters, MD

Charité - Universitätsmedizin Berlin
Dept. of Psychiatry and Psychotherapy, CBF
Hindenburgdamm 30, 12203 Berlin
Tel: +49 (0)30 – 450 517 628
Fax: +49 (0)30 – 450 517 942
Email: oliver.peters@charite.de



Occupational activity

Since 2014	Habilitation, <i>pro venia legendi</i> : Psychiatry and Psychotherapy
Since 2008	Branch Chief: Old age psychiatry and Geriatric Neuropsychiatry
Since 2008	Assistant medical director and attending psychiatrist at the Dept. of Psychiatry and Psychotherapy; Charité-CBF
2003-2008	Assistant doctor, Dept. of Psychiatry and Psychotherapy, Charité-CBF
2001-2003	Postdoctoral fellow, Cellular Neuroscience, Max-Delbrueck-Center, Berlin
1999-2001	Postdoctoral fellow and assistant doctor, Dept. of Neurology, Heinrich-Heine- University, Düsseldorf
1999	M.D. thesis
1994-1999	Studies in medicine, HU Berlin
1991-1993	Studies in medicine, FU Berlin

Experience in clinical research

Since 2014	Principal Investigator at the Berlin Institute of Health (BIH)
Since 2013	Coordinator of Sino-German Alzheimer's Disease Summit
Since 2011	Board Member of the German Dementia Competence Net (DCN)
Since 2010	National coordinator and principal investigator in clinical AD trials (Medivation, Roche, Affiris, Trx-Pharmaceuticals)
Since 2008	Principal Investigator in clinical AD trials (> 20, among others: Pfizer, Novartis, Genentech, Wyeth, Lilly, Janssen, Servier, Piramal)
Since 2008	Coordinator of the BMBF-funded SIMaMCI AD prevention-trial (IIT)
2007-2009	Managing director of the German Dementia Competence Network (DCN)

Activities in the scientific community

Since 2013	Member of the German Center for Neurodegenerative Diseases (DZNE)
Since 2008	Member of the European Alzheimer's Disease Consortium (EADC)
Since 2008	Member of the international society to advance Alzheimer research and treatment (ISTAART)
Since 2006	Faculty Member of "Berlin Medical Neuroscience"
2004-2007	Study coordinator of the Dementia Competence Net (DCN)
Since 2003	Member of the German Dementia Competence Net (DCN)

Basic and Clinical research fields

- Early diagnostic and treatment of cognitive impairment and dementia
- Clinical trials and Prevention of chronic neurodegeneration
- Biomarkers in chronic neurodegeneration

Cumulative impact/Citations/Third party funding

Cumulative Journal Impact Factor (ISI): 2009-2014	288,4
Number of Times Cited	1877 citations , 1597 since 2009 (according to google scholar) h-index: 22; i10-index:28

Selection of recent publications

- Jansen W.J., Ossenkoppele R., Knol D.L., Tijms B.M., Scheltens P., Verhey F.R.J., Visser P.J., Amyloid Biomarker Study Group, ... Peters O., et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. **JAMA-J Am Med Assoc.** 2015;313(19):1924-38.
- Heilmann S., Drichel D., Clarimon J., Fernández V., Lacour A., Wagner H., Thelen M., Hernández I., Fortea J., Alegret M., Blesa R., Mauleón A., Roca M.R., Kornhuber J., Peters O., et al. PLD3 in non-familial Alzheimer's disease. **Nature.** 2015;520(7545):E3-5
- Vos S.J.B., Verhey F., Frölich L., Kornhuber J., Wiltfang J., Maier W., Peters O., Rütther E., Nobili F., Morbelli S., Frisoni G.B., Drzezga A., Didic M., et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. **Brain.** 2015;138(Pt 5):1327-38.
- Wolfsgruber S., Jessen F., Koppa A., Kleineidam L., Schmidtke K., Frölich L., Kurz A., Schulz S., Hampel H., Heuser I., Peters O. et al.: Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. **Neurology.** 2015; 84(12):1261-8.
- Hooli BV, Parrado AR, Mullin K, Yip WK, Liu T, Roehr JT, Qiao D, Jessen F, Peters O, Becker T, Ramirez A, Lange C, Bertram L, Tanzi RE. The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk. **Neurology.** 2014 Oct 7;83(15):1353-8
- Bocchetta M, Galluzzi S, Kehoe PG, Aguera E, Bernabei R, Bullock R, Ceccaldi M, Dartigues JF, de Mendonça A, Didic M, ... Peters O, et al. The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. **Alzheimers Dement.** 2014 Aug 20.
- Ramirez A, van der Flier WM, Herold C, ... Peters O, et al. SUCLG2 identified as both a determinant of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. **Hum Mol Genet** 2014 Jul 15. pii: ddu372. [Epub ahead of print]
- Morgen K., Ramirez A., Frölich L., Tost H., Plichta M.M., Kölsch H., Rakebrandt F., Rienhoff O., Jessen F., Peters O., et al. Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer's disease. **Alzheimers Dement.** 2014;10(5 Suppl):S269-76.
- de Souza Silva MA, Lenz B, Rotter A, Biermann T, Peters O, Ramirez A, Jessen F, Maier W, Hüll M, Schröder J, Frölich L, Teipel S, Gruber O, Kornhuber J, Huston JP, Müller CP, Schäble S. Neurokinin3 receptor as a target to predict and improve learning and memory in the aged organism. **Proc Natl Acad Sci U S A.** 2013 Sep 10;110(37):15097-102.
- Peters O., Lorenz D., Fesche A., Schmidtke K., Hüll M., Perneczky R., Rütther E., Möller H.J., Jessen F., Maier W., Kornhuber J., Jahn H., Luckhaus C., Gertz H.J., Schröder J., Pantel J., Teipel S., Wellek S., Frölich L. & Heuser I. (2012) A combination of galantamine and memantine modifies cognitive function in subjects with amnesic MCI. **J Nutr Health Aging:** 16 544-8
- Peters O., Schipke C.G., Heuser I., Grimmer T., Sabbagh M.N., Sabri O., Hock C., Kunz M., Kuhlmann J., Reiningner C. & Blankenburg M. (2012) Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease. **Dement Geriatr Cogn:** 33 416-22
- Vom Berg J., Prokop S., Miller K.R., Obst J., Kälin R.E., Lopategui-Cabezas I., Wegner A., Mair F., Schipke C.G., Peters O., Winter Y., Becher B. & Heppner F.L. (2012) Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. **Nat Med:** 18 1812-9
- Wagner M., Wolf S., Reischies F.M., Daerr M., Wolfsgruber S., Jessen F., Popp J., Maier W., Hüll M., Frölich L., Hampel H., Perneczky R., Peters O., Jahn H., Luckhaus C., Gertz H.J., Schröder J., Pantel J., Lewczuk P., Kornhuber J. & Wiltfang J. (2012) Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. **Neurology:** 78 379-86
- Schipke CG, Prokop S, Heppner FL Heuser I, Peters O (2011) Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's Disease in human cerebrospinal fluid. **Dement Geriatr Cogn Disord** 31:139-45